Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus bronchial arterial infusion chemotherapy for stage IIIB NSCLC
ChiCTR2300068722Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: R0 resection rate. Started Feb 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300068722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068722.